SEP 07, 2019 5:36 AM PDT

A New Way To Fight Severe Peanut Allergies

WRITTEN BY: Amanda Mikyska

 

Over 1 million U.S. children have an allergy to peanuts, with exposure leading to anaphylaxis or even death.  Traces of peanut oil are found in every corner of the grocery store, even in unassuming food like soups and salad dressings, making avoidance very difficult.  

Now, researchers at Duke Medical Center and Massachusetts General Hospital have found a new approach to desensitize the immune system's attack on peanut protein.  The two methods currently available to help patients with severe nut allergies are either not effective, or come with severe side effects.  

First, a patch was developed which releases peanut protein into a patient gradually through the skin.  The hope is that it will raise the patient's tolerance to peanut exposure in food, effectively decreasing the consequence of accidental ingestion.  The method is not as effective as hoped, and though it is safe, it is not FDA-approved.

The more commonly used method is Oral Immunotherapy (OIT), which is a pill containing peanut protein, that patients take regularly to increase tolerance.  Patients begin by taking 0.5mg dose of peanut protein daily, and dosage increases to 300mg, or about equal to one peanut kernel.  That dosage is maintained for the remainder of the year-long study.  OIT is very effective for some people, but others suffered serious side effects and even dropped out of the study.  OIT treatment finished phase III clinical trials, and currently under review at the FDA.

Researchers at Duke Medical Center and Massachusetts General Hospital experimented with a new method to desensitize peanut allergies in children.  The therapy, called "sublingual immunotherapy" (SLIT), is a doctor administered drop of peanut protein under the patient's tongue.  Similar to OIT, the starting dosage is minuscule but gradually increased, then maintained over a long period.  By cutting out the digestive process, and allowing the body to directly absorb the protein, patients can build resistance with smaller doses than current treatments.

AllergyInsider

 

The SLIT study was done with eighteen participants, from 1 to 11 years old.  For six months, the participants were given increasing doses of peanut protein, then for the following six months, they continued dosage of the maximum amount of peanut protein.  The study concluded with a food test to see how desensitized their immune system was to peanuts.  Participants were given just 0.0002mg peanut protein to start and gradually increased to 2mg.    

The SLIT participants tolerated 10-20X as much peanut protein as it would take to make someone sick.  The increased tolerance gives people a buffer for food with traces of peanut protein that normally would trigger anaphylaxis.

Though SLIT was a smaller study than those used to test OIT, SLIT shows encouraging signs.  Data shows SLIT and OIT are about equally effective in desensitizing the immune system, and none of the eighteen participants had severe side effects or dropped out of the SLIT study.    The only side effect of SLIT was itchiness of the throat, which lasted for about 15 minutes following dosage but required no treatment.  The small doses, less than a tenth of what OIT patients are exposed to, make the SLIT method much safer.  

The labs at Duke and MGH are focusing on two other related studies.  A 4-year study with 55 patients that received up to a  4mg daily dose of peanut protein will be published in late 2019.  The other study focuses on children between 1 and 4 years old because this age group is more responsive to treatment and better maintain longterm desensitization to peanut protein.  

 

Sources: Kim et. al., TechnologyNetworks, MedPage Today

About the Author
  • Amanda graduated from the University of Massachusetts Boston with a degree in Biology. After working in research on creating biochemicals from genetically engineered yeast, she started freelance science writing while traveling the world. Now, Amanda is a Lab Manager and Research Assistant at the the University of Central Florida, studying the molecular phylogeny of parasitic wasps. She writes about the latest research in Neuroscience, Genetics & Genomics, and Immunology. Interested in working on solutions for food/water security, sustainable fuel, and sustainable farming. Amanda is an avid skier, podcast listener, and has run two triathlons.
You May Also Like
NOV 26, 2020
Immunology
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
NOV 26, 2020
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
  There’s a new weapon in the battle against lung cancer metastases: red blood cells equipped with nanopartic ...
JAN 06, 2021
Immunology
What's Causing Prostate Cancer Patients to Doze Off?
JAN 06, 2021
What's Causing Prostate Cancer Patients to Doze Off?
For prostate cancer patients, androgen deprivation therapy or ADT is a standard treatment aimed at stalling the growth o ...
FEB 02, 2021
Immunology
Tumors Under Seige by Cancer-Killing Salmonella
FEB 02, 2021
Tumors Under Seige by Cancer-Killing Salmonella
Salmonella is a genus of rod-shaped bacteria, often given a bad rap thanks to its association with food poisoning. But c ...
FEB 01, 2021
Microbiology
A Potential Leptospirosis Vaccine is Created
FEB 01, 2021
A Potential Leptospirosis Vaccine is Created
Spirochetes are a type of free-living, spiral-shaped bacteria, some of which are harmless and others that can cause dise ...
FEB 10, 2021
Drug Discovery & Development
Genetics Affect Response to Cancer Immunotherapy
FEB 10, 2021
Genetics Affect Response to Cancer Immunotherapy
Researchers have found that genetic factors may dictate as much as 20% of the efficacy of checkpoint inhibitors, a kind ...
APR 05, 2021
Cancer
Introducing DeepTCR, the deep-learning software for T-cell receptor sequencing data
APR 05, 2021
Introducing DeepTCR, the deep-learning software for T-cell receptor sequencing data
A team from the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center is introdu ...
Loading Comments...